Alphatec Holdings, Inc. (ATEC)
NASDAQ: ATEC · IEX Real-Time Price · USD
11.09
+0.03 (0.27%)
At close: Jul 19, 2024, 4:30 PM
11.10
+0.01 (0.09%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Alphatec Holdings Revenue
Alphatec Holdings had revenue of $511.63M in the twelve months ending March 31, 2024, with 31.51% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $138.48M with 26.92% year-over-year growth. In the year 2023, Alphatec Holdings had annual revenue of $482.26M with 37.45% growth.
Revenue (ttm)
$511.63M
Revenue Growth
+31.51%
P/S Ratio
3.03
Revenue / Employee
$609,808
Employees
839
Market Cap
1.55B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 482.26M | 131.40M | 37.45% |
Dec 31, 2022 | 350.87M | 107.66M | 44.26% |
Dec 31, 2021 | 243.21M | 98.35M | 67.89% |
Dec 31, 2020 | 144.86M | 31.43M | 27.71% |
Dec 31, 2019 | 113.43M | 21.73M | 23.70% |
Dec 31, 2018 | 91.69M | -10.05M | -9.87% |
Dec 31, 2017 | 101.74M | -18.51M | -15.39% |
Dec 31, 2016 | 120.25M | -14.14M | -10.52% |
Dec 31, 2015 | 134.39M | -20.24M | -13.09% |
Dec 31, 2014 | 154.63M | -50.10M | -24.47% |
Dec 31, 2013 | 204.72M | 8.45M | 4.30% |
Dec 31, 2012 | 196.28M | -1.43M | -0.72% |
Dec 31, 2011 | 197.71M | 26.10M | 15.21% |
Dec 31, 2010 | 171.61M | 50.99M | 42.28% |
Dec 31, 2009 | 120.62M | 28.44M | 30.85% |
Dec 31, 2008 | 92.18M | 12.15M | 15.18% |
Dec 31, 2007 | 80.03M | 6.03M | 8.14% |
Dec 31, 2006 | 74.01M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.62B |
Supernus Pharmaceuticals | 597.40M |
InMode | 466.26M |
Kiniksa Pharmaceuticals | 301.77M |
MannKind | 224.60M |
Schrödinger | 188.48M |
Avadel Pharmaceuticals | 55.14M |
Spyre Therapeutics | 688.00K |
ATEC News
- 12 days ago - ATEC to Report Second Quarter Financial Results on July 31, 2024 - Business Wire
- 2 months ago - ATEC Reports First Quarter 2024 Financial Results and Raises Full-Year Guidance - Business Wire
- 2 months ago - ATEC to Present at Upcoming Conferences - Business Wire
- 3 months ago - ATEC to Report First Quarter Financial Results on May 7, 2024 - Business Wire
- 3 months ago - Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales - Business Wire
- 5 months ago - ATEC Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Highlights - Business Wire
- 6 months ago - ATEC Announces Record Preliminary Revenue Results for 2023 and 2024 Revenue Guidance - Business Wire
- 7 months ago - ATEC to Present at the 2024 J.P. Morgan Healthcare Conference - Business Wire